- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03014700
Fibrinogen Concentrate vs Cryoprecipitate
Repurposing of Fibrinogen Concentrate as a Cost-Effective and Safe Hemostatic Agent in Infants Undergoing Cardiac Surgery on Cardiopulmonary Bypass
One of the most common hemostatic derangements in pediatric open- heart surgery is an acute acquired hypofibrinogenemia. This compromises fibrin clot generation and platelet aggregation, resulting in increased bleeding and allogenic blood transfusions.
Currently, fresh frozen plasma and cryoprecipitate are used to supplement fibrinogen in pediatric cardiac patients. We propose that replacing cryoprecipitate with fibrinogen concentrate will be as effective in treating post-CPB bleeding and will decrease total blood product exposure when used as part of a blood transfusion algorithm.
We plan to include all patients undergoing cardiac surgery on CPB less than 12 months and a fibrinogen level <250mg/dL while on bypass.
We hope to demonstrate that fibrinogen concentrate is at least as effective as the standard of care in the management of peri- operative bleeding in neonatal patients undergoing cardiopulmonary bypass. If we are able to demonstrate that fibrinogen is at least as effective as the standard of care, then we would plan a multi-center trial to demonstrate the safety and efficacy of this medication. If we are able to demonstrate that fibrinogen concentrate is effective, fibrinogen concentrate could replace allogenic products and potentially decrease transfusion related morbidity in mortality in this population.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients under 12 months of age requiring cardiopulmonary bypass surgery will be approached for the study. Patients with a pre- existing coagulopathy, including unexplained bleeding or history of clotting, will be excluded. Prior to the study beginning, patients will be randomized to our standard transfusion algorithm with cryoprecipitate or fibrinogen concentrate. As is standard of care, laboratory tests will be sent at standard times points
- after the induction of anesthesia,
- after initiation of bypass,
- after separation from bypass and administration of protamine, and transfusion of either fibrinogen concentrate or cryoprecipitate
- on arrival to the ICU. These laboratory tests include hematocrit, arterial blood gas, chemistry, thromboelastogram (TEG) and fibrinogen. Additional laboratory tests will be sent as indicated by the clinical scenario to determine transfusion requirements. For patients enrolled in the study, we will standardize the anesthetic management, cardiopulmonary bypass protocol, and transfusion thresholds in the operating room and ICU. We will collect demographic data, intraop and post-op laboratory values, bypass times, intraop and post op transfusion data, chest tube output, adverse events, and length of ventilation, ICU stay and hospital stay.
For patients randomized to the study arm (fibrinogen concentrate), the fibrinogen level measured on bypass will be used to calculate the appropriate dose of fibrinogen concentrate to achieve a level of 300mg/dL after separation from bypass. Fibrinogen concentrate will replace cryoprecipitate in our post-operative transfusion algorithm. If the patient has continued bleeding based on laboratory values and clinical situation, the patient will be given cryoprecipitate as a rescue measure. Patients not on the study protocol will receive our normal transfusion algorithm.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University Medical Center
-
-
Georgia
-
Emory, Georgia, United States, 30322
- Laura Downey
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Neonates of at least 32 weeks of gestational age and infants up to 12 months of age with the diagnosis of congenital heart disease, requiring open heart surgery with cardiopulmonary bypass
Exclusion Criteria:
- Pre-existing coagulopathy, including unexplained bleeding or history of clotting
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Cryoprecipitate Arm
Subject will be administered Cryoprecipitate to control bleeding after open heart surgery when randomized to Cryoprecipitate group
|
Subject will be administered Cryoprecipitate to control bleeding after open heart surgery when randomized to Cryoprecipitate group
|
ACTIVE_COMPARATOR: Fibrinogen Concentrate Arm
Subject will be administered Fibrinogen Concentrate to control bleeding after open heart surgery when randomized to Fibrinogen Concentrate group
|
Subject will be administered Fibrinogen Concentrate to control bleeding after open heart surgery when randomized to Fibrinogen Concentrate group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total Units of Intraoperative Allogenic Donor Transfusions (ADT) Administered During Procedure Through ICU Arrival.
Time Frame: From administration of the drug during surgery to ICU arrival postoperatively (up to 24 hours)
|
For our study, 1 donor exposure = 1 unit of blood product transfusion.
A blood product includes red blood cells, fresh frozen plasma, cryoprecipitate, and platelets.
|
From administration of the drug during surgery to ICU arrival postoperatively (up to 24 hours)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Chest Tube Output
Time Frame: From administration end of surgery to 24 hours post operatively
|
Volume of chest tube drainage evaluated over first 24 hours post operatively
|
From administration end of surgery to 24 hours post operatively
|
Hours of Mechanical Ventilation
Time Frame: From administration of the drug during surgery to extubation in the ICU (up to 30 days)
|
From administration of the drug during surgery to extubation in the ICU (up to 30 days)
|
|
Length of Stay in Intensive Care Unit (ICU)
Time Frame: From administration of the drug during surgery to discharge from the ICU (up to 3 months)
|
From administration of the drug during surgery to discharge from the ICU (up to 3 months)
|
|
Length of Stay in Hospital
Time Frame: From administration of the drug during surgery to discharge from the hospital (up to 6 months)
|
From administration of the drug during surgery to discharge from the hospital (up to 6 months)
|
|
Count of Participants Who Died Within 30 Days Following Procedure
Time Frame: From administration of the drug to 30 days following surgery
|
From administration of the drug to 30 days following surgery
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Glyn D Williams, MBChB, FFA, Stanford University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 36374
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Congenital Heart Disease
-
University of UlsterBelfast Health and Social Care TrustCompletedCongenital Heart Disease | Congenital Heart Defect | Adult Congenital Heart DiseaseUnited Kingdom
-
Children's Hospital Medical Center, CincinnatiNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Disease CongenitalUnited States
-
Vanderbilt University Medical CenterEnrolling by invitationCongenital Heart Disease | Congenital Heart Defect | Congenital Heart MalformationsUnited States
-
YHAlattarNot yet recruitingCritical Congenital Heart Disease
-
University Hospital TuebingenCompletedComplex Congenital Heart DiseaseGermany
-
The Hospital for Sick ChildrenCompletedCongenital Heart Disease (CHD)Canada
-
University College, LondonSociety for Cardiothoracic Surgery in Great Britain & Ireland; British Congenital...Unknown
-
University of California, DavisCompletedCyanotic Congenital Heart DiseaseUnited States
-
Assistance Publique Hopitaux De MarseilleRecruitingComplex Congenital Heart DiseaseFrance
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI); Boston Children's HospitalEnrolling by invitation
Clinical Trials on Cryoprecipitate
-
Weill Medical College of Cornell UniversityCerus CorporationRecruitingBleeding | HypofibrinogenemiaUnited States
-
University Health Network, TorontoCompleted
-
Gold Coast Hospital and Health ServiceEmergency Medicine Foundation; National Blood Authority; Australian Red CrossUnknownHemorrhage | Trauma | Coagulopathy | PediatricsAustralia
-
Gold Coast Hospital and Health ServiceEmergency Medicine Foundation; National Blood Authority; Australian Red CrossCompleted
-
Australian and New Zealand Intensive Care Research...Australian and New Zealand Intensive Care Society Clinical Trials Group; Australasian... and other collaboratorsRecruitingTrauma | Coagulopathy | Haemorrhagic ShockAustralia
-
University of Sao PauloCSL BehringCompletedBlood Coagulation Disorders | Cardiac Surgical Procedures | Fibrinogen | CryoprecipitateBrazil
-
University of VirginiaOctapharmaCompletedBleeding | Pediatric HDUnited States
-
Weill Medical College of Cornell UniversityTerminatedCoagulopathyUnited States
-
Bryan CottonQueen Mary University of London; NHS Blood and TransplantCompletedTrauma InjuryUnited Kingdom, United States
-
CSL BehringWithdrawnAfibrinogenemia | Hypofibrinogenemia | Fibrinogen Deficiency